Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

  • Read more about Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

  • Read more about Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

  • Read more about A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute

  • Read more about Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute

A Study of Baricitinib (LY3009104) in Children With COVID-19

  • Read more about A Study of Baricitinib (LY3009104) in Children With COVID-19

NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

  • Read more about NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3

  • Read more about Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3

Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)

  • Read more about Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)

  • Read more about Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

  • Read more about Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 142
  • Page 143
  • Page 144
  • Page 145
  • Current page 146
  • Page 147
  • Page 148
  • Page 149
  • Page 150
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA